Results 31 to 40 of about 233,415 (250)

A case of abiraterone acetate withdrawal syndrome after initiation of upfront abiraterone therapy for high‐risk prostate cancer

IJU Case Reports, 2023
Introduction Transient decrease in serum prostate‐specific antigen level can occur after abiraterone acetate withdrawal in male patient with metastatic castration‐resistant prostate cancer.
Masaru Tani, Yujiro Hayashi, Airi Miki, Teppei Wakita, Yuki Horibe, Yoichi Kakuta, Koichi Tsutahara, Tetsuya Takao   +7 more
doaj   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

Beyond the Number: Interpreting Prostate-Specific Antigen Elevation in the Context of Prostate Inflammation [PDF]

Urogenital Tract Infection
Prostate-specific antigen (PSA) is indispensable but not cancer specific; inflammation, benign prostatic hyperplasia, urinary retention, ejaculation, and instrumentation can all elevate PSA and complicate cancer risk assessment.
Byoungkyu Han, Ki-Hyuck Moon
doaj   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

PROSTATE-SPECIFIC ANTIGEN

Urologic Clinics of North America, 1997
Prostate specific antigen is the "gold standard" prostate tissue marker. Based on a reviews of the literature, we present the metabolism, method and lassay clinical use for diagnosis, staging and prostate cancer as well as for monitoring response to treatment. The authors also discuss some situations able to increase the level of this marker.
Lori J. Sokoll, Daniel W. Chan
openaire   +3 more sources

Prostate Specific Antigen (PSA): The Historical Perspective

McGill Journal of Medicine, 2020
In 1970, shortly after joining Roswell Park Memorial Institute, the New York State institute for the study of malignant diseases, the author initiated investigations on the use of tumor cell products for diagnosis and therapy of cancer.
T. Ming Chu
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Review of Clinical Manifestations of Biochemically-advanced Prostate Cancer Cases

Asian Journal of Surgery, 2005
To review the pattern of initial clinical manifestation of patients who present with biochemically-advanced prostate carcinoma. Methods: A review of 39 prostate cancer patients with initial prostate specific antigen (PSA) levels of more than 400 ng/mL ...
Edmund Chiong, Alvin Fung Wean Wong, Yiong Huak Chan, Chong Min Chin   +3 more
doaj   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms

European Urology Open Science, 2021
Prostate-specific antigen (PSA) density is an established prognostic marker for prostate cancer. We investigated whether the inclusion of PSA density or prostate volume in the Memorial Sloan Kettering Cancer Center nomograms improves the prediction of ...
Michael Tzeng, Emily Vertosick, Spyridon P. Basourakos, James A. Eastham, Behfar Ehdaie, Peter T. Scardino, Andrew J. Vickers, Jim C. Hu   +7 more
doaj   +1 more source